세계의 초붕괴제 시장 보고서 : 제품 유형, 제형, 치료 분야 및 지역별(2024-2032년)

The global superdisintegrants market size reached US$ 416.8 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 733.4 Million by 2032, exhibiting a growth rate (CAGR) of 6.3% during 2024-2032.

Superdisintegrants are modified disintegrants added in drug formulations to facilitate the breakup or disintegration of tablets or capsules into smaller particles. They assist in increasing the absorption of the drug and the solubility of active pharmaceutical ingredients (APIs) in the body, thereby reducing the disintegration time or oral solid dosage forms and enhancing their efficiency. They are utilized at a low level in the solid dosage form, generally 1- 10% by weight relative to the total weight of the dosage unit. Presently, they are available in synthetic and natural variants and used in many therapeutic areas, such as cardiovascular, infectious, hematological, neurological, gastrointestinal diseases, and inflammatory diseases.

Superdisintegrants Market Trends:

Solid dosage medicines currently hold a significant share in the pharmaceutical industry. This, coupled with the rising number of people suffering from various age-related and chronic diseases, represents one of the key factors strengthening the growth of the market. Moreover, the extensive usage of superdisintegrants in the production of orally disintegrating tablets (ODTs) for antipsychotics, antidepressants, antimigraine, and sedatives is offering lucrative growth opportunities to industry investors. Apart from this, features like high compatibility, improved bioavailability, and efficient compressibility are catalyzing the demand for superdisintegrants worldwide. Additionally, leading players are considerably investing in product development and innovation of novel formulations to retain a competitive edge in the market. Besides this, stringent regulations are propelling the use of safer alternatives in the pharmaceutical industry, which is assisting in the wider acceptance of natural superdisintegrants around the world. Furthermore, the growing burden of neurological disorders, in confluence with the increasing popularity of telemedicine on account of the coronavirus disease (COVID-19) outbreak, is anticipated to impel the market growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global superdisintegrants market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product, type, dosage form, and therapeutic areas.

Breakup by Product:

• Croscarmellose Sodium
• Crospovidone
• Sodium Starch Glycolate
• Ion Exchange Resin
• Modified Cellulose
• Others

Breakup by Type:

• Natural Superdisintegrant
• Synthetic Superdisintegrant
• Others

Breakup by Dosage Form:

• Tablets and Capsules
• Mouth-Dissolving Films

Breakup by Therapeutic Areas:

• Gastrointestinal
• Cardiovascular
• Neurology
• Oncology
• Hematology
• Others

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Asahi Kasei Corporation, Ashland Global Specialty Chemicals Inc., Avantor Inc., BASF SE, Corel Pharma Chem, DFE Pharma GmbH & Co. KG, DuPont de Nemours Inc., JRS Pharma GmbH & Co. KG, Merck KGaA, Nippon Soda Co. Ltd., Roquette Freres and Sigachi Industries Limited.

Key Questions Answered in This Report:

• How has the global superdisintegrants market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the global superdisintegrants market?
• What are the key regional markets?
• What is the breakup of the market based on the product?
• What is the breakup of the market based on the type?
• What is the breakup of the market based on the dosage form?
• What is the breakup of the market based on the therapeutic areas?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the industry?
• What is the structure of the global superdisintegrants market and who are the key players?
• What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Superdisintegrants Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product

• 6.1 Croscarmellose Sodium
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Crospovidone
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Sodium Starch Glycolate
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Ion Exchange Resin
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 Modified Cellulose
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast
• 6.6 Others
  • 6.6.1 Market Trends
  • 6.6.2 Market Forecast

7 Market Breakup by Type

• 7.1 Natural Superdisintegrant
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Synthetic Superdisintegrant
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Others
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast

8 Market Breakup by Dosage Form

• 8.1 Tablets and Capsules
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Mouth-Dissolving Films
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast

9 Market Breakup by Therapeutic Areas

• 9.1 Gastrointestinal
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Cardiovascular
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Neurology
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast
• 9.4 Oncology
  • 9.4.1 Market Trends
  • 9.4.2 Market Forecast
• 9.5 Hematology
  • 9.5.1 Market Trends
  • 9.5.2 Market Forecast
• 9.6 Others
  • 9.6.1 Market Trends
  • 9.6.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 United States
    • 10.1.1.1 Market Trends
    • 10.1.1.2 Market Forecast
  • 10.1.2 Canada
    • 10.1.2.1 Market Trends
    • 10.1.2.2 Market Forecast
• 10.2 Asia-Pacific
  • 10.2.1 China
    • 10.2.1.1 Market Trends
    • 10.2.1.2 Market Forecast
  • 10.2.2 Japan
    • 10.2.2.1 Market Trends
    • 10.2.2.2 Market Forecast
  • 10.2.3 India
    • 10.2.3.1 Market Trends
    • 10.2.3.2 Market Forecast
  • 10.2.4 South Korea
    • 10.2.4.1 Market Trends
    • 10.2.4.2 Market Forecast
  • 10.2.5 Australia
    • 10.2.5.1 Market Trends
    • 10.2.5.2 Market Forecast
  • 10.2.6 Indonesia
    • 10.2.6.1 Market Trends
    • 10.2.6.2 Market Forecast
  • 10.2.7 Others
    • 10.2.7.1 Market Trends
    • 10.2.7.2 Market Forecast
• 10.3 Europe
  • 10.3.1 Germany
    • 10.3.1.1 Market Trends
    • 10.3.1.2 Market Forecast
  • 10.3.2 France
    • 10.3.2.1 Market Trends
    • 10.3.2.2 Market Forecast
  • 10.3.3 United Kingdom
    • 10.3.3.1 Market Trends
    • 10.3.3.2 Market Forecast
  • 10.3.4 Italy
    • 10.3.4.1 Market Trends
    • 10.3.4.2 Market Forecast
  • 10.3.5 Spain
    • 10.3.5.1 Market Trends
    • 10.3.5.2 Market Forecast
  • 10.3.6 Russia
    • 10.3.6.1 Market Trends
    • 10.3.6.2 Market Forecast
  • 10.3.7 Others
    • 10.3.7.1 Market Trends
    • 10.3.7.2 Market Forecast
• 10.4 Latin America
  • 10.4.1 Brazil
    • 10.4.1.1 Market Trends
    • 10.4.1.2 Market Forecast
  • 10.4.2 Mexico
    • 10.4.2.1 Market Trends
    • 10.4.2.2 Market Forecast
  • 10.4.3 Others
    • 10.4.3.1 Market Trends
    • 10.4.3.2 Market Forecast
• 10.5 Middle East and Africa
  • 10.5.1 Market Trends
  • 10.5.2 Market Breakup by Country
  • 10.5.3 Market Forecast

11 SWOT Analysis

• 11.1 Overview
• 11.2 Strengths
• 11.3 Weaknesses
• 11.4 Opportunities
• 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 Asahi Kasei Corporation
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
    • 15.3.1.3 Financials
    • 15.3.1.4 SWOT Analysis
  • 15.3.2 Ashland Global Specialty Chemicals Inc.
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
    • 15.3.2.3 Financials
    • 15.3.2.4 SWOT Analysis
  • 15.3.3 Avantor Inc.
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
    • 15.3.3.3 Financials
  • 15.3.4 BASF SE
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
    • 15.3.4.3 Financials
    • 15.3.4.4 SWOT Analysis
  • 15.3.5 Corel Pharma Chem
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
  • 15.3.6 DFE Pharma GmbH & Co. KG
    • 15.3.6.1 Company Overview
    • 15.3.6.2 Product Portfolio
  • 15.3.7 DuPont de Nemours Inc.
    • 15.3.7.1 Company Overview
    • 15.3.7.2 Product Portfolio
    • 15.3.7.3 Financials
    • 15.3.7.4 SWOT Analysis
  • 15.3.8 JRS Pharma GmbH & Co. KG
    • 15.3.8.1 Company Overview
    • 15.3.8.2 Product Portfolio
  • 15.3.9 Merck KGaA
    • 15.3.9.1 Company Overview
    • 15.3.9.2 Product Portfolio
    • 15.3.9.3 Financials
    • 15.3.9.4 SWOT Analysis
  • 15.3.10 Nippon Soda Co. Ltd.
    • 15.3.10.1 Company Overview
    • 15.3.10.2 Product Portfolio
    • 15.3.10.3 Financials
    • 15.3.10.4 SWOT Analysis
  • 15.3.11 Roquette Freres
    • 15.3.11.1 Company Overview
    • 15.3.11.2 Product Portfolio
    • 15.3.11.3 SWOT Analysis
  • 15.3.12 Sigachi Industries Limited
    • 15.3.12.1 Company Overview
    • 15.3.12.2 Product Portfolio